A Phase III Randomised, Double-Blind Trial To Evaluate The Effect Of 12 Weeks Treatment Of Once Daily Empaglifozin 10mg Compared With Placebo On Exercise Ability And Heart Failure Symptoms, In Patients With Chronic Heart Failure With Reduced Ejection Fraction (Hfref) (EMPERIAL – Reduced)

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/50043/SVHM-2019-164332(v3)
NMA SSA Reference Number: SSA/50043/MonH-2019-169531(v1)
Monash Health Ref: RES-19-0000-245X
Effective start/end date4/04/193/04/24


  • clinical trial
  • phase 3 study
  • treatment efficacy
  • heart disease